Showing 1351-1360 of 1620 results for "".
- American Academy of Optometry Announces Barbara Caffery, OD, PhD, FAAO, as Presidenthttps://modernod.com/news/american-academy-of-optometry-names-barbara-caffery-od-phd-faao-as-president/2479665/The American Academy of Optometry has named Barbara Caffery, OD, PhD, FAAO, the incoming President of the American Academy of Optometry. Dr. Caffery was formally inducted during the Academy’s annual meeting in San Antonio, Texas on November 10, 2018. She is the first Canadian woman to serve as pr
- SECO International Names J. Max Ernst, OD, as 2020 Presidenthttps://modernod.com/news/seco-international-names-j-max-ernst-od-as-2020-president/2476329/SECO International, the world’s largest educational conference, has announced that J. Max Ernst, OD, will become the next SECO International President. Dr. Ernst will officially accept the honor during the House of Delegates meeting, held during SECO 2019, Saturday, February 23, from 3:15 pm-5 pm
- Fred Dubick, OD, Named Optometrist of the Year by California Optometric Associationhttps://modernod.com/news/burbank-eye-doctor-named-optometrist-of-the-year-by-california-optometric-association/2479011/The California Optometric Association (COA) announced that Fred Dubick, OD, MBA, FAAO, has been named the “Optometrist of the Year.” Dr. Dubick is an optometrist and owner of StudioEyes Optometry with locations in Burban
- OD-OS Achieves Revocation of Iridex MicroPulse Patenthttps://modernod.com/news/od-os-achieves-revocation-of-iridex-micropulse-patent/2480020/OD-OS has achieved the revocation of the MicroPulse Patent (Patent no EP1856774) by Iridex Corporation in oral proceedings at the European Patent office held last Friday in Munich, Germany according to an OD-OS news release. With its successful opposition, OD-OS has cleared the path to man
- OD-OD Introduces a New Learning App for Retinal Laser Treatmenthttps://modernod.com/news/od-od-introduces-a-new-learning-app-for-retinal-laser-treatment/2479529/To address growing demand for interactive learning technology, OD-OS has developed a tool for implementing a better approach to retinal laser treatment: The Navigate App. Navigate is a free, interactive tool designed to support residents and team education—both onsite and online. The platf
- ScienceBased Health Announces Expansion of its Optometry Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-announces-expansion-of-its-optometry-clinical-advisory-panel/2478537/ScienceBased Health (SBH), a provider of nutraceuticals for eye health, announced the addition of Tracy Doll, OD, FAAO; Scott Hauswirth, OD, FAAO; and Justin Schweitzer, OD, FAAO, to its Clinical Advisory Panel. “We’re honored to welcome these distinguished practitioners to our Clini
- OD-OS Introduces the Navilas expertLibrary Forum for Retina Specialistshttps://modernod.com/news/od-os-introduces-the-navilas-expertlibrary-forum-for-retina-specialists/2480093/OD-OS has introduced a new forum for retina specialists – the Navilas expertLibrary. The Navilas expertLibrary is an exclusive forum where leading retinal physicians share their day-to-day experience with this novel navigated retinal laser technology, according to OD-OS. Interested parties
- Pioneering Ophthalmologist William J. Lahners Passes Awayhttps://modernod.com/news/pioneering-ophthalmologist-william-j-lahners-passes-away/2480517/William J. Lahners, MD, FACS, Medical Director, Center for Sight, in Sarasota, Florida, passed away on Friday at the age of 53.
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<
- Novartis Receives Permanent J-code for Beovuhttps://modernod.com/news/novartis-receives-permanent-j-code-for-beovu/2477192/Novartis announced that it has received a permanent J-code for Beovu (brolucizumab-dbll) injection, effective January 1, 2020. With the permanent J-code, retina specialists may now receive more timely reimbursement for Beovu injections, facilitating access for appropriate patients to this